Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Assets: 2019-2025

Historic Assets for Avidity Biosciences (RNA) over the last 6 years, with Sep 2025 value amounting to $2.1 billion.

  • Avidity Biosciences' Assets rose 30.07% to $2.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.1 billion, marking a year-over-year increase of 30.07%. This contributed to the annual value of $1.6 billion for FY2024, which is 148.81% up from last year.
  • According to the latest figures from Q3 2025, Avidity Biosciences' Assets is $2.1 billion, which was up 55.90% from $1.4 billion recorded in Q2 2025.
  • Avidity Biosciences' Assets' 5-year high stood at $2.1 billion during Q3 2025, with a 5-year trough of $290.5 million in Q2 2021.
  • Moreover, its 3-year median value for Assets was $1.3 billion (2024), whereas its average is $1.2 billion.
  • Per our database at Business Quant, Avidity Biosciences' Assets declined by 18.24% in 2021 and then spiked by 186.27% in 2024.
  • Over the past 5 years, Avidity Biosciences' Assets (Quarterly) stood at $427.6 million in 2021, then spiked by 49.40% to $638.8 million in 2022, then decreased by 1.60% to $628.6 million in 2023, then spiked by 148.81% to $1.6 billion in 2024, then surged by 30.07% to $2.1 billion in 2025.
  • Its last three reported values are $2.1 billion in Q3 2025, $1.4 billion for Q2 2025, and $1.5 billion during Q1 2025.